fda import alert glp-1 semaglutide tirzepatide green list 66-80 apis Compounded & 2025: Safe Use Guide 行业研究| FDA针对GLP-1原料药出台“Green List”（绿名单）医药新闻-ByDrug-一站式医药资源共享中心-医药魔方

This is where dietitians play a vital role

Buyer takeaway: where required, the brand notes that laboratory blood testing may be part of the evaluation before a prescription is written

Adverse effects of tirzepatide are similar to GLP-1 RAs

Research design and methods Using the data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases, the differences in adverse events across specific subgroups concerning reporter type, sex, age, dose, indication, report year, onset time, and outcome were investigated using the ROR algorithm and Chi-Square Test/Fishers exact test

Pharmacovigilance and signal detection FAERS semaglutide disproportionality (broad): A FAERS-based disproportionality analysis of semaglutide reports through mid-2023 identified multiple unexpected adverse event signals and explicitly notes that some signals were not mentioned in the drug insert, including polycystic ovaries. The analysis highlights typical spontaneous-reporting limitations (missing age, outcome data)

On April 2, 2025, the FDA cited Empower for a pyridoxine batch released despite detected microbial growth, along with broader aseptic-processing deficiencies at its Houston 503B facility